USA - NASDAQ:TVGN - US88165K1016 - Common Stock
The current stock price of TVGN is 0.6005 USD. In the past month the price decreased by -22.95%. In the past year, price decreased by -74.66%.
|  Symbol  |  Company Name  |  TA  |  FA  |  PE  |  Market Cap  | 
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.55 | 403.13B | ||
| AMGN | AMGEN INC | 13.39 | 157.20B | ||
| GILD | GILEAD SCIENCES INC | 14.46 | 146.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.79 | 107.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.53 | 69.32B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 345.82 | 58.93B | ||
| ARGX | ARGENX SE - ADR | 61.91 | 50.51B | ||
| INSM | INSMED INC | N/A | 41.05B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.97 | 33.85B | ||
| NTRA | NATERA INC | N/A | 26.52B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.16B | ||
| BIIB | BIOGEN INC | 8.94 | 21.93B | 
 Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company is headquartered in Warren, New Jersey and currently employs 18 full-time employees. The company went IPO on 2021-11-04. The firm is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.
TEVOGEN BIO HOLDINGS INC
15 Independence Boulevard, Suite #210
WARREN NEW JERSEY US
Employees: 18
Phone: 16468078832
Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company is headquartered in Warren, New Jersey and currently employs 18 full-time employees. The company went IPO on 2021-11-04. The firm is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.
The current stock price of TVGN is 0.6005 USD. The price decreased by -2.5% in the last trading session.
TVGN does not pay a dividend.
TVGN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
TEVOGEN BIO HOLDINGS INC (TVGN) operates in the Health Care sector and the Biotechnology industry.
TEVOGEN BIO HOLDINGS INC (TVGN) will report earnings on 2025-11-10.
ChartMill assigns a fundamental rating of 1 / 10 to TVGN. TVGN has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months TVGN reported a non-GAAP Earnings per Share(EPS) of 0.38. The EPS increased by 375% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 337.72% | ||
| ROE | N/A | ||
| Debt/Equity | N/A | 
7 analysts have analysed TVGN and the average price target is 10.2 USD. This implies a price increase of 1598.58% is expected in the next year compared to the current price of 0.6005.